Insider Selling: Natera, Inc. (NASDAQ:NTRA) CFO Sells $235,955.70 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 1,866 shares of the business’s stock in a transaction on Thursday, October 31st. The shares were sold at an average price of $126.45, for a total transaction of $235,955.70. Following the transaction, the chief financial officer now directly owns 68,851 shares of the company’s stock, valued at approximately $8,706,208.95. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, October 28th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The shares were sold at an average price of $118.21, for a total transaction of $146,343.98.
• On Friday, October 25th, Michael Burkes Brophy sold 691 shares of Natera stock. The shares were sold at an average price of $118.81, for a total transaction of $82,097.71.
• On Wednesday, October 23rd, Michael Burkes Brophy sold 496 shares of Natera stock. The shares were sold at an average price of $119.09, for a total transaction of $59,068.64.
• On Monday, October 21st, Michael Burkes Brophy sold 608 shares of Natera stock. The shares were sold at an average price of $120.76, for a total transaction of $73,422.08.

Natera Trading Up 2.6 %

NASDAQ:NTRA opened at $124.16 on Monday. The stock has a market cap of $15.36 billion, a PE ratio of -50.68 and a beta of 1.53. The stock’s 50-day moving average is $123.40 and its two-hundred day moving average is $112.38. Natera, Inc. has a fifty-two week low of $40.17 and a fifty-two week high of $133.54. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.39. The business had revenue of $413.35 million during the quarter, compared to analysts’ expectations of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The firm’s quarterly revenue was up 58.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.97) EPS. As a group, equities research analysts forecast that Natera, Inc. will post -1.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Natera

Several large investors have recently made changes to their positions in NTRA. Farallon Capital Management LLC grew its stake in shares of Natera by 13.6% in the 2nd quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock valued at $483,034,000 after buying an additional 532,874 shares in the last quarter. First Light Asset Management LLC lifted its holdings in Natera by 295.9% in the 1st quarter. First Light Asset Management LLC now owns 656,708 shares of the medical research company’s stock worth $60,063,000 after purchasing an additional 490,822 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Natera by 257.6% in the 2nd quarter. AQR Capital Management LLC now owns 651,523 shares of the medical research company’s stock worth $70,553,000 after purchasing an additional 469,327 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. acquired a new stake in Natera in the 1st quarter worth approximately $33,956,000. Finally, Nikko Asset Management Americas Inc. acquired a new stake in Natera in the 1st quarter worth approximately $33,938,000. Institutional investors own 99.90% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. BTIG Research lifted their price objective on shares of Natera from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Friday, August 9th. StockNews.com cut shares of Natera from a “hold” rating to a “sell” rating in a research note on Friday, October 25th. Robert W. Baird boosted their price target on shares of Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Leerink Partners boosted their price target on shares of Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Finally, TD Cowen boosted their price target on shares of Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $125.69.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.